{"entity":{"id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","aka":[],"tldr":"A phase 2 trial of Bexobrutideg in chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting.","summary":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) is a phase 2 interventional study registered as NCT07221500 by Nurix Therapeutics, Inc., with 100 participants planned, started 2025-10-15 and due to reach its primary completion in 2028-01. Interventions recorded: NX-5948.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07221500","url":"https://clinicaltrials.gov/study/NCT07221500"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["bexobrutideg"],"companies":["nurix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07221500","phase":"2","setting":"A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)","sponsor":"Nurix Therapeutics, Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct07221500/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/"}],"company":[{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/"}]}}